AQST News and Press, Aquestive Therapeutics Inc. From 03/11/20

Aquestive Therapeutics (NASDAQ: AQST ): Q4 GAAP EPS of -$0.48 misses by $0.10 . Revenue of $16.42M (-2.4% Y/Y) beats by $0.58M . Press Release More news on: Aquestive Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, ,

Expects to submit IND application for AQST-108 (epinephrine) in second quarter 2020 and commence pharmacokinetics (PK) clinical trials before end of 2020 FDA sets Libervant™ (diazepam) Buccal Film PDUFA goal date of September 27, 2020 Reported full year 2019 revenues and adjusted ...

WARREN, N.J., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced that it ...

vTv Therapeutics (NASDAQ: VTVT ) +80%  on positive TTP399 data . More news on: vTv Therapeutics Inc., Taubman Centers, Inc., Edgewell Personal Care Company, Stocks on the move, Read more ...

Unisys (NYSE: UIS ) +39%  on being acquired by Science Applications International. More news on: Unisys Corporation, Myomo, Inc., China Xiangtai Food Co., Ltd., Stocks on the move, , Read more ...

Aquestive Therapeutics (NASDAQ: AQST ) is up  9%  premarket on modest volume on the heels of its announcement that the FDA has signed off on the abbreviated 505(b)(2) registration pathway for AQST-108, an oral sublingual film formulation of epinephrine for the potential treatment...

Pre-IND Meeting on AQST-108 Completed FDA Confirmed AQST-108 To Be Reviewed Under 505(b)(2) No Additional Clinical Studies Would Be Required Prior to Opening Proposed IND Pivotal Pharmacokinetic (PK) Clinical Trials Planned To Be Initiated Before Year End 2020 WARREN, N.J., Feb. 06, ...

These Penny Stocks Are Expecting To Release New Data This Week If there’s one thing investing in penny stocks has taught us, it’s to look for potential catalysts anywhere you can find them. Sometimes it’s easier said than done, to be honest. But proper research is a skil...

Gainers: Adaptimmune Therapeutics (NASDAQ: ADAP )  +242% . More news on: Adaptimmune Therapeutics plc, Aethlon Medical, Inc., BioCardia, Inc., Stocks on the move, Read more ...

Acasti Pharma (NASDAQ: ACST )  -66%  after  unsuccessful results  from a Phase 3 TRILOGY 1 trial. More news on: Acasti Pharma Inc., Stage Stores, Inc., Five Below, Inc., Stocks on the move, Read more ...